Clinicians may soon have a new tool to aid patients with refractory acute myeloid leukemia (AML). Researchers at the Perelman School of Medicine at the University of Pennsylvania and Penn’s Abramson Cancer Center report in The Lancet Oncology that the drug gilteritinib had a favorable safety profile and showed consistent FLT3 inhibition in patients with relapsed or refractory AML.
The American Society of Clinical Oncology’s annual meeting, one of the most important cancer conferences of the year, concluded June 7th. This year’s theme was ‘collective wisdom: the future of patient-centered care and research,’
The American Society of Hematology (ASH), the premier event for scientific exchange in the field of hematology, recently concluded its annual meeting in Orlando, Florida. Oral and poster presentations featured the latest research in malignant and non-malignant hematology that are considered the best of the thousands submitted for the annual meeting.